Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01AYF
|
|||
| Former ID |
DIB012432
|
|||
| Drug Name |
ND-1.1
|
|||
| Synonyms |
Avian influenza vaccine, West Coast Biologicals; Ad-HA-dsRNA; H5N1 avian influenza vaccine (oral, adenoviral vector,dsRNA adjuvant), Vaxart
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Influenza virus infection [ICD-11: 1E30-1E32] | Phase 1 | [1] | |
| Company |
Glaxosmithkline; novavax; vaxart
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Influenza Hemagglutinin (Influ HA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01698060) Immunogenicity of ND1.1 by Delivery Directly to the Ileum. U.S. National Institutes of Health. | |||
| REF 2 | An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.